Signaling Pathways and Emerging Therapies in Multiple Myeloma. Curr Hematol Malig Rep 2016 Apr;11(2):156-64
Date
02/29/2016Pubmed ID
26922744DOI
10.1007/s11899-016-0315-4Scopus ID
2-s2.0-84962224784 (requires institutional sign-in at Scopus site) 17 CitationsAbstract
Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.
Author List
Ramakrishnan V, D'Souza AAuthor
Anita D'Souza MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntineoplastic Agents
Humans
Multiple Myeloma
NF-kappa B
Proto-Oncogene Proteins c-akt
Signal Transduction
TOR Serine-Threonine Kinases
